Log on / register
Feedback | Support | My details
The Future of Smallpox Vaccination: is MVA the key?
Slifka MK
Med Immunol 2005 Mar 1, 4:2
[Full text] [PubMed] [Related articles]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.
Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB
J Virol 2006 Aug, 80:7676-87
 [PubMed Central] [PubMed] [Related articles]
2.
Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.
García AD, Meseda CA, Mayer AE, Kumar A, Merchlinsky M, Weir JP
Clin Vaccine Immunol 2007 Aug, 14:1032-44
 [PubMed Central] [PubMed] [Related articles]
3.
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.
Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang K, Shen T, Wang H, Tian P, Zhang L, Chen Z
PLoS One 2009, 4:e4180
 [PubMed Central] [PubMed] [Related articles]
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.